Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIPEC Carboplatin in Advanced Ovarian Cancer
NCT02199171Phase 1Completed
- Sponsor
- University of California, Irvine
- Start
- Jul 2014
- Primary completion
- Oct 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carboplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by University of California, Irvine. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Jul 2014; status: completed.
02
Drugs
carboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02199171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02199171.